Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Emerging Treatments for Alzheimer's Disease: A Review of Clinical Trials and New Drug Approvals
*Corresponding Author: Zhang Xin, Department of Neurology, University of Bern, Switzerland, Email: xinzhai802@gmail.comReceived Date: Jan 01, 2025 / Published Date: Jan 30, 2025
Citation: Zhang X (2025) Emerging Treatments for Alzheimer’s Disease: A Reviewof Clinical Trials and New Drug Approvals J Dement 9: 256.
Copyright: © 2025 Zhang X. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Abstract
Alzheimer’s disease (AD) remains a significant public health challenge, with an increasing prevalence worldwide. Despite extensive research, effective treatment options remain limited. However, recent advancements in clinical trials and drug development have led to the emergence of promising therapeutic agents. This review examines the latest treatments for AD, focusing on disease-modifying therapies (DMTs), monoclonal antibodies targeting amyloid-beta, taubased treatments, and novel small molecules. It highlights key clinical trials, regulatory approvals, and their implications for patient care. The review also discusses challenges in drug development, including safety concerns, efficacy limitations, and accessibility issues. Recent FDA approvals of aducanumab and lecanemab have ignited hope for modifying disease progression, yet controversy remains regarding their clinical benefits. Emerging non-pharmacological approaches, such as gene therapy and neurostimulation, also show potential. This review provides a comprehensive overview of current advancements and their impact on future AD treatment strategies.
